Oral Multiple Sclerosis Therapies Spark Excitement, Concern
April 29, 2011|Clinical Psychiatry News
Author and Disclosure Information
FROM THE ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY
Dr. Kita said she has no relevant conflicts of interest. Dr. Greenberg disclosed financial relationships with DioGenix, Biogen Idec (which is developing BG-12), EMD Serono (which is developing cladribine), Teva Neurosciences (which is developing laquinimod), and the Greater Good Foundation.
Sanofi-Aventis, which is developing teriflunomide, funded the TEMSO trial. Dr. Miller, Dr. Wolinsky, and many of their associates in the study disclosed relationships with Sanofi-Aventis and with numerous other companies that make therapies for multiple sclerosis. Three of their co-investigators were employees of Sanofi-Aventis.
